The findings of controlled trials on use of intravenous immunoglobulin G (IV IgG) to treat myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) are generally viewed as representing mixed results. On detailed review, a clearer picture emerges, which suggests that the potential therapeutic value of this intervention has been underestimated.
In 2018, the Norwegian ME Association undertook a large survey of severely ill ME patients. We wanted to…
Hard to believe that patients with ME have been treated so poorly for decades, but they have, and…
Last year on his birthday, we presented Alem Matthees with an award and framed certificate on behalf of…
Why is this important? The Government has chosen to ‘focus on new claimants’ by providing an extra £20…
(CNN)Shortly after 11 a.m. on December 16, 2019, Cindy Siegel Shepler drew her last breath in a spartan…
The ME Association is funding a study led by Prof Sarah Tyson of University of Manchester (who also…